Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

Table 1 Clinical applications of PD-1 and PD-L1 antibodies

Antibodies	Dosages^a	Indications^b
Pembrolizumab	200 mg over 60 min q3 weeks	Melanoma, NSCLC, HNSCC, urothelial carcinoma, Hodgkin’s lymphoma, MSI-high cancer, gastric cancer
Pembrolizumab	200 mg over 60 min q3 weeks carboplatin/pemetrexed	First line combination therapy for metastatic non-squamous NSCLC
Nivolumab	240 mg over 60 min q2 weeks	Melanoma, NSCLC, renal cell carcinoma, urothelial carcinoma, MSI-high /dMMR CRC, HCC
Nivolumab	3 mg/kg over 60 min q2 weeks	Hodgkin’s lymphoma, HNSCC
Atezolizumab	1200 mg over 60 min q3 weeks	Urothelial carcinoma, NSCLC
Durvalumab	10 mg/kg over 60 min q2 weeks	Urothelial carcinoma
Avelumab	10 mg/kg over 60 min q2 weeks	Merkel cell carcinoma, urothelial carcinoma

Abbreviations: NSCLC non-small cell lung cancer, HNSCC head/neck squamous cell carcinoma, MSI microsatellite instability; dMMR deficient mismatch repair gene, CRC colorectal cancer, HCC hepatocellular carcinoma, min minute, q3w every 3 weeks
^aFfor pediatric dosing and for combination dosage and schedules, please refer to full prescribing information for each individual agent
^bFor exact indications, please refer to full prescribing information for each individual agent

ISSN: 1756-8722